NYMX实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (7 Jul 2023 @ 04:00):

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally...

Stats
今日成交量	881 574
平均成交量	134 777
市值	18.24M
EPS	$0.0100 ( 2023-08-15 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.86
ATR14	$0.161 (16.48%)

Insider Trading

Date	Person	Action	Amount	type
2023-04-27	Robinson James George	Buy	40 000	Common Stock
2023-04-25	Robinson James George	Buy	40 000	Common Stock
2023-04-25	Robinson James George	Buy	40 000	Common Stock
2022-05-02	Robinson James George	Buy	1 151 515	Warrant
2021-04-22	Robinson James George	Buy	200	Common Stock

INSIDER POWER
100.00
Last 100 transactions
Buy: 1 546 252 \| Sell: 0

音量相关性

長: -0.08 (neutral)

短: -0.02 (neutral)

Signal:(67.127) Neutral

Nymox Pharmaceutical Corp 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Nymox Pharmaceutical Corp 相关性 - 货币/商品

0.31
( neutral )

0.81
( strong )

0.00
( neutral )

0.68
( moderate )

-0.03
( neutral )

-0.25
( neutral )

Nymox Pharmaceutical Corp 财务报表

Annual	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-0.0735

FY	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-0.0735

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.150

FY	2020
营收:	$5 000.00
毛利润:	$1 000.00 (20.00 %)
EPS:	$-0.160

Financial Reports:

No articles found.

Nymox Pharmaceutical Corp

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease, as well as researches and develops drug treatments for Alzheimer's disease. The company was founded in 1989 and is headquartered in Nassau, the Bahamas.